Academic Journal
Paradigm Shifts in Cystic Fibrosis Newborn Screening and Care in Infancy.
| Title: | Paradigm Shifts in Cystic Fibrosis Newborn Screening and Care in Infancy. |
|---|---|
| Authors: | Wyatt ML; Division of Pulmonary and Sleep Medicine, Seattle Children's Hospital, Center for Respiratory Biology and Therapeutics, University of Washington, Seattle, WA, USA. Electronic address: mackenzielanwyatt@gmail.com., Clarion J; Division of Pulmonary and Sleep Medicine, Seattle Children's Hospital, University of Washington, Seattle, WA, USA., McGarry M; Division of Pulmonary and Sleep Medicine, Seattle Children's Hospital, Center for Respiratory Biology and Therapeutics, University of Washington, Seattle, WA, USA. |
| Source: | Advances in pediatrics [Adv Pediatr] 2026 Aug; Vol. 73 (1), pp. 161-178. Date of Electronic Publication: 2026 May 20. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: Mosby Country of Publication: United States NLM ID: 0370436 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1926 (Electronic) Linking ISSN: 00653101 NLM ISO Abbreviation: Adv Pediatr Subsets: MEDLINE |
| Imprint Name(s): | Publication: Chicago Il : Mosby Original Publication: New York, Interscience [etc.] |
| MeSH Terms: | Cystic Fibrosis*/diagnosis , Cystic Fibrosis*/therapy , Cystic Fibrosis*/genetics , Neonatal Screening*/methods, Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Humans ; Infant, Newborn ; Infant |
| Abstract: | There have been advances in the care of children with cystic fibrosis (CF) that allow for early disease identification and intervention in early childhood. Universal and the rise of modulator therapy have revolutionized CF care, so the life expectancy in children with CF has improved. With the changing landscape in advances in CF care, there is uncertainty in interpretation of tests and clinical phenotypes that are indeterminate for CF diagnosis. (Copyright © 2026 Elsevier Inc. All rights reserved.) |
| Competing Interests: | Disclosure The research of Dr M.L. Wyatt is funded by the Cystic Fibrosis Foundation, United States (CFF) Clinical Fellowship Award, grant number WYATT24B0 and WYATT25D0, the Rosenfeld Funds, and the Corkery Endowment. The work of Dr M. McGarry is funded by the National Institutes of Health, United States (NIH), grant number 5K23HL133437-05, and the Cystic Fibrosis Foundation (CFF), grant number MCGARR16A0. |
| Contributed Indexing: | Keywords: Cystic fibrosis (CF); Cystic fibrosis screen positive; Cystic fibrosis transmembrane conductance regulator (CFTR)-Related metabolic syndrome (CRMS); Health equity; Highly effective modulator therapy (HEMT); Inconclusive diagnosis (CFSPID); Modulators; Newborn screening (NBS) |
| Substance Nomenclature: | 126880-72-6 (Cystic Fibrosis Transmembrane Conductance Regulator) |
| Entry Date(s): | Date Created: 20260721 Date Completed: 20260721 Latest Revision: 20260721 |
| Update Code: | 20260722 |
| DOI: | 10.1016/j.yapd.2026.02.002 |
| PMID: | 42481088 |
| Database: | MEDLINE |
| ISSN: | 1878-1926 |
|---|---|
| DOI: | 10.1016/j.yapd.2026.02.002 |